{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:00:17Z","timestamp":1792000817394,"version":"4.4.0"},"reference-count":14,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T00:00:00Z","timestamp":1646179200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,2,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In TANGO, switching to dolutegravir\/lamivudine (DTG\/3TC) demonstrated long-term noninferior efficacy vs continuing tenofovir alafenamide\u2013based regimens in treatment-experienced adults with HIV-1. The phase 3 SALSA study evaluated efficacy and safety of switching to DTG\/3TC compared with continuing various 3-\/4-drug current antiretroviral regimens (CARs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Adults with HIV-1 RNA &amp;lt;50 copies\/mL and no previous virologic failure were randomized (1:1, stratified by baseline third agent class) to switch to once-daily fixed-dose combination DTG\/3TC or continue CAR (primary endpoint: proportion of participants with HIV-1 RNA \u226550 copies\/mL at week 48; Snapshot, intention-to-treat\u2013exposed population, 5% noninferiority margin).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 493 adults (39% women; 39% aged \u226550 years; 19% African American\/African heritage; 14% Asian) were randomized to switch to DTG\/3TC (n\u2005=\u2005246) or continue CAR (n\u2005=\u2005247). At week 48, 1 (0.4%) participant in the DTG\/3TC group and 3 (1.2%) in the CAR group had HIV-1 RNA \u226550 copies\/mL (Snapshot), demonstrating noninferiority (adjusted difference, \u22120.8%; 95% CI, \u22122.4%, .8%). Zero participants met confirmed virologic withdrawal criteria; therefore, no resistance testing was performed. Drug-related adverse events were more frequent with DTG\/3TC (20%) than CAR (6%) through week 48 but comparable post\u2013week 24 (5% vs 2%, respectively). Proximal tubular renal function and bone turnover biomarkers improved with DTG\/3TC. Both groups had generally minimal changes in lipids and inflammatory biomarkers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Switching to DTG\/3TC was noninferior to continuing CAR for maintaining virologic suppression at week 48 with no observed resistance, supporting the efficacy, good safety, and high barrier to resistance of DTG\/3TC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trials Registration<\/jats:title>\n                    <jats:p>www.clinicaltrials.gov, NCT04021290.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciac130","type":"journal-article","created":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T15:10:34Z","timestamp":1646147434000},"page":"720-729","source":"Crossref","is-referenced-by-count":178,"title":["Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir\/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized Trial"],"prefix":"10.1093","volume":"76","author":[{"given":"Josep M","family":"Llibre","sequence":"first","affiliation":[{"name":"Hospital Universitari Germans Trias i Pujol , Barcelona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Brites","sequence":"additional","affiliation":[{"name":"Universidade Federal da Bahia , Salvador , Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Yu","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Taoyuan General Hospital, Ministry of Health and Welfare , Taoyuan , Taiwan"},{"name":"Institute of Public Health, School of Medicine, National Yang-Ming Chiao Tung University , Taipei , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olayemi","family":"Osiyemi","sequence":"additional","affiliation":[{"name":"Triple O Research Institute PA , West Palm Beach, Florida , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Galera","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednico Universitario Virgen de la Arrixaca , Murcia , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Hocqueloux","sequence":"additional","affiliation":[{"name":"Centre Hospitalier R\u00e9gional d\u2019Orl\u00e9ans , Orl\u00e9ans , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Maggiolo","sequence":"additional","affiliation":[{"name":"ASST Papa Giovanni XXIII , Bergamo , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf","family":"Degen","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum Hamburg-Eppendorf , Hamburg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Taylor","sequence":"additional","affiliation":[{"name":"Birmingham Heartlands Hospital , Birmingham , United Kingdom"},{"name":"University of Birmingham , Birmingham , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Blair","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , Durham, North Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Choy","family":"Man","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , Durham, North Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Wynne","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , Durham, North Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Oyee","sequence":"additional","affiliation":[{"name":"GSK , Brentford , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Underwood","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , Durham, North Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lloyd","family":"Curtis","sequence":"additional","affiliation":[{"name":"GSK , Brentford , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilda","family":"Bontempo","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , Durham, North Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"van Wyk","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , Brentford , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,3,2]]},"reference":[{"key":"2023021818301466000_","doi-asserted-by":"crossref","first-page":"113","DOI":"10.18683\/germs.2017.1115","article-title":"2-Drug regimens in HIV treatment: pharmacological considerations.","volume":"7","author":"Back","year":"2017","journal-title":"Germs"},{"key":"2023021818301466000_","author":"Panel on Antiretroviral Guidelines for Adults and Adolescents.","year":"2021"},{"key":"2023021818301466000_","author":"European AIDS Clinical Society."},{"key":"2023021818301466000_","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1001\/jama.2020.17025","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the International Antiviral Society\u2013USA panel.","volume":"324","author":"Saag","year":"2020","journal-title":"JAMA"},{"key":"2023021818301466000_","first-page":"14","volume-title":"Program and abstracts of HIV Drug Therapy Glasgow 2020 (virtual)","author":"van Wyk","year":"2020"},{"key":"2023021818301466000_","volume-title":"Program and abstracts of 11th IAS Conference on HIV Science (virtual)","author":"van Wyk","year":"2021"},{"key":"2023021818301466000_","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1093\/cid\/ciz1243","article-title":"Efficacy and safety of switching to dolutegravir\/lamivudine fixed-dose 2-drug regimen vs continuing a tenofovir alafenamide\u2013based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: phase 3, randomized, noninferiority TANGO study.","volume":"71","author":"van Wyk","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2023021818301466000_","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJMe2114651","article-title":"Striving for diversity in research studies.","volume":"385","author":"Rubin","year":"2021","journal-title":"N Engl J Med"},{"key":"2023021818301466000_","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/hiv.13050","article-title":"Effectiveness and safety of dolutegravir two-drug regimens in virologically suppressed people living with HIV: a systematic literature review and meta-analysis of real-world evidence.","volume":"22","author":"Punekar","year":"2021","journal-title":"HIV Med"},{"key":"2023021818301466000_","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/cid\/ciz999","article-title":"Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials.","volume":"71","author":"Sax","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2023021818301466000_","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1097\/QAI.0000000000002650","article-title":"Impact of efavirenz mid-dose plasma concentration on long-term weight change among virologically suppressed people living with HIV.","volume":"87","author":"Huang","year":"2021","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2023021818301466000_","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ijid.2020.01.035","article-title":"Efficacy and safety of the regimens containing tenofovir alafenamide versus tenofovir disoproxil fumarate in fixed-dose single-tablet regimens for initial treatment of HIV-1 infection: a meta-analysis of randomized controlled trials.","volume":"93","author":"Tao","year":"2020","journal-title":"Int J Infect Dis"},{"key":"2023021818301466000_","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/QAD.0000000000003070","article-title":"Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy-naive adults with HIV-1 infection.","volume":"36","author":"Cahn","year":"2022","journal-title":"AIDS"},{"key":"2023021818301466000_","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1007\/s40121-021-00522-7","article-title":"HIV treatment with the two-drug regimen dolutegravir plus lamivudine in real-world clinical practice: a systematic literature review.","volume":"10","author":"Patel","year":"2021","journal-title":"Infect Dis Ther"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciac130\/48741249\/ciac130.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/76\/4\/720\/49255964\/ciac130.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/76\/4\/720\/49255964\/ciac130.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T03:02:15Z","timestamp":1700276535000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/76\/4\/720\/6541246"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,2]]},"references-count":14,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,3,2]]},"published-print":{"date-parts":[[2023,2,18]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciac130","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,2,15]]},"published":{"date-parts":[[2022,3,2]]}}}